Calcium Phosphate Cement As Bone Void Filler
CALCIUM PHOSPHATE CEMENT AS BONE VOID FILLER - a Prospective Cohort Study in Patients Indicated for Long Bone and Extremity Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Lisboa, Portugal
- Hospital Lusiadas Lisboa
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients requiring bone grafting after post-traumatic or surgically created bone defects afflicting the long bones and extremities.
- Give written informed consent to participate in the study and be willing to comply with the protocol requirements.
- Able to verbalize and differentiate regarding the location and intensity of pain.
- Physical and mental availability to meet the clinical and radiographic follow-up schedule.
Exclusion Criteria:
- Serious infection within two months before surgery.
- Active malignancy, Cellulitis, Osteomyelitis, Osteomyelitis, Bone metastasis, Other bone metabolic diseases.
- Primary bone tumors and contraindications in performing an X-ray or CTscan.
- Women of childbearing potential who are, or plan to become, pregnant during the time of the study.
- The subject is unable or not willing to complete follow-up visits and examination for the duration of the study.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Calcium Phosphate Cement (CPC)
Evaluation of CPC in long bone & extremities
|
Filling bone defects in current clinical practice
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Radiological healing
Time Frame: 3 months
|
Bone healing observable by x-ray/CT-scan.
Assessment of trabecular defects: modified Neer classification.
Assessment of cortical defects: modified RUST.
|
3 months
|
|
Radiological healing
Time Frame: 6 months
|
Bone healing observable by x-ray/CT-scan.
Assessment of trabecular defects: modified Neer classification.
Assessment of cortical defects: modified RUST.
|
6 months
|
|
Radiological healing
Time Frame: 9 months
|
Bone healing observable by x-ray/CT-scan.
Assessment of trabecular defects: modified Neer classification.
Assessment of cortical defects: modified RUST.
|
9 months
|
|
Radiological healing
Time Frame: 12 months
|
Bone healing observable by x-ray/CT-scan.
Assessment of trabecular defects: modified Neer classification.
Assessment of cortical defects: modified RUST.
|
12 months
|
|
Radiological healing
Time Frame: 18 months
|
Bone healing observable by x-ray/CT-scan.
Assessment of trabecular defects: modified Neer classification.
Assessment of cortical defects: modified RUST.
|
18 months
|
|
Radiological healing
Time Frame: 24 months
|
Bone healing observable by x-ray/CT-scan.
Assessment of trabecular defects: modified Neer classification.
Assessment of cortical defects: modified RUST.
|
24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number and description of any adverse event during the follow-up
Time Frame: 3 months
|
Record and description of any adverse event during the follow-up that reflects the safety of the bone graft substitute.
|
3 months
|
|
Number and description of any adverse event during the follow-up
Time Frame: 6 months
|
Record and description of any adverse event during the follow-up that reflects the safety of the bone graft substitute.
|
6 months
|
|
Number and description of any adverse event during the follow-up
Time Frame: 9 months
|
Record and description of any adverse event during the follow-up that reflects the safety of the bone graft substitute.
|
9 months
|
|
Number and description of any adverse event during the follow-up
Time Frame: 12 months
|
Record and description of any adverse event during the follow-up that reflects the safety of the bone graft substitute.
|
12 months
|
|
Number and description of any adverse event during the follow-up
Time Frame: 18 months
|
Record and description of any adverse event during the follow-up that reflects the safety of the bone graft substitute.
|
18 months
|
|
Number and description of any adverse event during the follow-up
Time Frame: 24 months
|
Record and description of any adverse event during the follow-up that reflects the safety of the bone graft substitute.
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Nuno A Ribeiro, MD, Hospital Lusiadas Lisboa
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2019.04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.